Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Every Three Week Docetaxel (Taxotere®) In Subjects With Androgen Independent Prostate Cancer

NCT01378091 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT01378091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01378091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Every Three Week Docetaxel (Taxotere®) In Subjects With Androgen Independent Prostate Cancer
Lead sponsor
Columbia University
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2005
Completion date
September 30, 2013
Enrollment
64 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer